Cardiol Therapeutics Inc. CRDL
At closeNov 5, 2026, 4:11 PM EST
After hours · Nov 5, 4:11 PM ET
- YTD
- -2.88%
- 1 year
- -15.00%
- Market cap
- 112.58M
- EPS (ttm)
- -0.25
- Shares out
- 81.60M
- Forward P/E
- -4.03
- YTD return
- -2.88%
- 1-year return
- -15.00%
- Volume
- 733.74K
- Avg volume
- 1.36M
- Open
- 1.00
- Previous close
- 1.01
- Day's range
- 0.915 – 1.03
- 52-week range
- 0.88 – 2.34
- Beta
- 0.70
- Analysts
- Buy
- Price target
- 8.70 (+839.0%)
- Earnings date
- Aug 12, 2024
1D -0.0835 (-8.27%)
Key statistics
- Enterprise value
- 103.33M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.63M
- Total cash
- 24.02M
- Total debt
- 164.27K
- Return on equity
- -108.43%
- Short % of float
- 1.06%
- 50-day average
- 1.70
- 200-day average
- 1.95
Analyst view
Consensus: buy
- Target (low)
- 7.80
- Target (mean)
- 8.70
- Target (high)
- 9.78
- Strong buy4
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.10 | -0.13 | -0.03 | -30.00% |
| Aug 12, 2024 | Jun 1, 2024 | -0.10 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -0.10 | -0.07 | +0.03 | +30.00% |
| May 14, 2024 | Mar 1, 2024 | -0.06 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.06 | -0.10 | -0.04 | -66.67% |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.09 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 26, 2024 | Roth MKM | init | — | Buy |
| Jun 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- cardiolrx.com
News
Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC 
HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target 
Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis 
Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy 
Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds 
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery 
Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities 
Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission 
Cardiol Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference 
12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on CRDL — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tejara Capital Ltd | 2.17% | 1,771,270 | 2.21M | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 1.43% | 1,170,869 | 1.46M | Sep 29, 2024 |
| MMCAP International, Inc. SPC | 0.97% | 795,625 | 994.53K | Sep 29, 2024 |
| Lion Street Advisors, LLC | 0.33% | 273,281 | 341.60K | Sep 29, 2024 |
| Foundations Investment Advisors, Llc | 0.20% | 161,950 | 202.44K | Sep 29, 2024 |
| MGO One Seven, LLC | 0.12% | 100,000 | 125.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Pure Cannabis ETF | 1.28% | 1,047,249 | 1.31M | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 52,435 | 65.54K | Oct 30, 2024 |